DAVID EMERSON JORDEN
CIK 1313516 · CEO/CFO · last filed 2026-06-05
DAVID EMERSON JORDEN is a CEO/CFO who has filed 162 SEC Form 4 insider transactions across 4 companies since 2008. Across all open-market trades the lifetime net is +$1.6M, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
162
$1.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PLx Pharma Inc. (PLXP) Delisted | Acting Chief Financial Officer | 151,913 | $0.09 | $13.2K | $225.0K | 2 | 2017-06-16 |
| Acer Therapeutics Inc. (OPXAW) Delisted | Acting Chief Financial Officer | 293,456 | — | — | $155.3K | 24 | 2013-09-26 |
| ConnectOne Bancorp, Inc. (CNBC) Delisted | Director | 5,765,000 | — | — | $29.2K | 1 | 2011-03-09 |
| Nuo Therapeutics, Inc. (GTF) Delisted | Director | 5,402,858 | — | — | $1.18M | 82 | 2011-01-26 |
Recent Filings
162 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | — | Grant (A) | +13,245 | $14.5K | |
| 2026-01-05 | — | Mixed | +99,619 | -$1 | |
| 2025-12-03 | — | Sell (S) | −200,000 | -$300.0K | |
| 2025-08-04 | — | Mixed | +171,397 | $40.0K | |
| 2022-11-14 | — | Sell (S) | −162,500 | -$243.8K | |
| 2022-05-02 | — | Grant (A) | +10,532 | $10.5K | |
| 2022-04-26 | — | Grant (A) | — | $0 | |
| 2019-01-03 | — | Grant (A) | — | $0 | |
| 2018-08-13 | — | Grant (A) | — | $0 | |
| 2017-08-14 | — | Buy (P) | +247,500 | $55.0K |